UroLift

DEVICE7 trials

Sponsors

NeoTract, Inc., Olympus Corporation of the Americas, Northwell Health, University of Texas Southwestern Medical Center, Royal Marsden NHS Foundation Trust

Conditions

Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia (BPH)Prostate Cancer

Unknown Phase

Urodynamic Feasibility Study Utilizing the UroLift® System

CompletedNCT04271020

NeoTract, Inc.Benign Prostatic Hyperplasia

Start: 2018-10-25End: 2019-11-27Updated: 2020-06-11

Comparing UroLift Experience Against Rezūm

Active, not recruitingNCT04338776

NeoTract, Inc.Benign Prostatic Hyperplasia

Start: 2021-01-22End: 2025-12-31Target: 120Updated: 2025-10-14

Post-Market Study to Assess iTind Safety in Comparison to UroLift

RecruitingNCT04757116

Olympus Corporation of the AmericasBenign Prostatic Hyperplasia (BPH)

Start: 2022-09-26End: 2031-12-31Target: 206Updated: 2025-10-31

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

SuspendedNCT05148156

Northwell HealthBenign Prostatic Hyperplasia

Start: 2021-12-15End: 2028-03-01Target: 20Updated: 2026-01-27

UroLift System With SAbR for Prostate Cancer and BPH

CompletedNCT05311527

University of Texas Southwestern Medical CenterProstate Cancer

Start: 2023-01-11End: 2025-10-29Updated: 2025-10-31

A Study Comparing Urolift and TURP Ahead of Radiotherapy in Men With Urinary Symptoms Secondary to Prostate Enlargement

Royal Marsden NHS Foundation TrustProstate Cancer

Start: 2023-05-09End: 2025-05-09Target: 45Updated: 2023-09-01

Comparing Rezum and Urolift

RecruitingNCT06820606

Chinese University of Hong KongProstate Cancer

Start: 2025-01-01End: 2027-12-31Target: 120Updated: 2025-02-14

Related Papers

<b>CO</b>mparing Urolift and <b>S</b>tandard <b>T</b>ransurethral resection of prostate <b>A</b>head of <b>R</b>adiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility study

BMJ Open2023-10-011 citations